Compare AbCellera Biologics Inc (ABCL) vs Aegon Ltd. (AEG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Aegon Ltd. — how do they compare? AbCellera Biologics Inc trades at $9.07 (market cap $2.85B), while Aegon Ltd. trades at $9.4 (market cap $14.16B). The key difference: Aegon Ltd. is far larger — about 5× AbCellera Biologics Inc's market cap, and Aegon Ltd. pays a 4.9% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | AEG | |
|---|---|---|
Market Cap | $2.85B | $14.16B |
Sector | Health | Financials |
52-Week High | $9.76 | $9.53 |
52-Week Low | $2.78 | $6.79 |
Enterprise Value | $2.45B | $15.31B |
Dividend Yield | — | 4.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
AEG trades at $9.53, up 0.74% on the day, with a bullish technical signal driven by moving averages. The company reported revenue of $19.52 billion in 2024 with a net income margin of 3.64%, and recent earnings show mixed results with beats in Q2 and Q3 2025 but a miss in Q4. A dividend of $0.25 is scheduled for July 2026. The balance sheet shows total assets of $327.39 billion and a debt-to-asset ratio improving to 1.46 in 2024.
The outlook is cautiously optimistic with a P/E of 13.74 and P/S of 0.58 suggesting reasonable valuation, but risks include volatile cash flows and competitive pressures. Analyst sentiment is mixed with 27.78% buy ratings, highlighting potential for growth amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Aegon Ltd.
Aegon is a Netherlands-headquartered insurance company with core operations that stretch across the U.S., Netherlands, and United Kingdom. The business also holds peripheral ventures in Spain, Portugal, Brazil, and China.
Read more on AEG →
